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S rq Seventeen alkylamine ammine dicarboxylatodichloroplatinum(IV) complexes of general sucture
c,t,c[tCAOCOR1)2NH3(RNH2)J where R = aiphatic or aliyclic and RI = aiphatic or aromatic, have ben
evahlated against L1210 cell lines with acqured -ssta1c to cisplatin (10-fold), tetraplatin (34-fold) or
carboplatin (14-fold) using an in vitro growth-delay assay. All of these compounds overcame cisatin,
tetraplatin and carboplatin resistance. Potency i d as the number ofcarbon atoms in the axial aliphatic
ligands (R) increas, for example com JM216 (R = cydohexyl, RI = CHI, ICs, = 1.2 m) with JM274
(R = cydohexyl, RI = n-C4H,, IC,q = 0.05 aM) against the parent sensitive lne (L1210/S). The most active
compounds were those possesing aromatic ligands at RI, regardls of whether R = ahphatic or alicycic, for
example JM244 (R = n-C3H7, RI =C*H5, ICg = 0.028 am) and JM2644 (R =c-C1H1I, RI =CjHS,
IC5n
= 0.031 aM) against L12101S. For an alicychc alkylamine series in which R is varied from c-C3H7 to
C-C7H13, with RI = n-C,H7 for each compound, cytotoxic potency was maximisd at c-CjH1 (JM221,
IC5. = 0.06FM against L1210/S). Preliminary biochemical sudies, at equitoxic doses, comparing JM221
(0.1FIM) with cisplatin (0.6 aM) identified five times more platinum associated with JM221 treated cells and 1.5
times more platinum bound to the DNA of JM221-treated cells. The lpophilic properies of some of these
platinum(V) dicarboxylates may contribute to both the potency and circumvention of rsstance by these
compounds.
Cisplatin [cis-diamminedichloroplatinum(II)] is a valuable
anti-cancer drug, particularly for the treatment of ovarian
and testicular tumours (Ozols & Young, 1984; Rosenberg,
1985). However, cilatin-related toxicities, together with the
emergene of tumour resistance, has limited its usefulness
(Gottlieb & Drewinko, 1975; Krakoff, 1979). Carboplatin
[c-dammicycobl,lI-dicarboxylato)platinum(ll)] was
developed as a second-generation platinum drug, which,
although devoid of many of the toxic side-effects ofcisplatin,
retained a similar spectrum ofclinical activity (Harrap, 1985;
Mangioni et al., 1989). More recently, attention has switched
to the platinum (IV) compounds iproplatin [cis-dichloro-
trans-dihydroxo-cas-bis(isopropylamine)platinum (IV)J and
tetraplatin [(trans-d,l,2-diaminocylohexanetetrachloro-
platinu(IV) both of which have been intrduced into cinical
studies (Bramwell et al., 1985; Schilder et al., 1987). It has
been shown that these platinum(IV) compounds undergo
reduction to the platinum(II) species in biological systems
(Gibbons et al., 1989; Pendyala et al., 1990). This appears to
be a requirement for the major event leading to cytotoxicity,
i.e. platinum binding to DNA (Pendyala et al., 1988). Tetra-
platin was selected for clinical development following the
observation that platinum complexes with a diaminocyclo-
hexane ligand retain activity against cisplatin-resistant L1210
and P388 murine leukaemias (Burchenal et al., 1979; Rose et
al., 1982). Recently, we have shown that ammine/amine
(mixed amines) platinum(II) compounds based on the struc-
tures of cisplatin and carboplatin and diamminetetrachloro-
platinum(IV) overcome acquired resistance to isplatin (10-
fold) but not to tetraplatin (34-fold) in L1210 cells (Orr et al.,
1993). However, trans-dihydroxodichloroplatinum(IV) mixed
amines together with iproplatin and the parent diammine
overcome resistance to both cisplatin and tetraplatin in these
ceUl lines. These studies have now been extended to evaluate
the potency of novel mne/amine platinum(IV) dicarboxy-
lates against cisplatin-, tetraplatin- and the newly developed
carboplatin-resistant (Nicolson et al., 1992) L1210 cell lines
and to examine cellular accumulation and DNA binding,
comparing cisplatin with one of these compounds
(JM221).
Materials sod mtod
All platinum complexes reported herein were synthesised and
supplied by the Johnson Matthey Technology Centre
(Reading, Berks, UK) and the Johnson Matthey Biomedical
Research Centre (West Chester, PA, USA) (Giandomenico et
al., 1991). Phenol (Ultra Pure) was obtained from Gibco/
BRL (Uxbridge, Middksex, UK) and all other reagent
chemicals from Sigma (Poole, Dorset, UK). Cell culture
medium and serum were purchased from ICN Flow (High
Wycombe, Buckinghamshire, UK).
Cell lines andgrowth delay/cell survival assays
Parent sensitive L1210 murine leukaemia cells and their
platinum-resistant counterparts, possessing acqred resis-
tance to either cisplatin (L1210/cis), carboplatin (L1210/
carbo) or tetraplatin (L1210/tetra), were grown in RPMI-
1640 medium supplemented with 10% horse serum, 2 mM
glutamine and antibiotics (100 U ml-l penicillin and
0.1 mgml' streptomycin). The development and mainten-
ance of resistance to each agent have been described else-
where (Nicolson et al., 1992; Orr et al., 1993). Growth-delay
assays were initiated at a cell density of 5 x 104ml
1 and
cells ained in logarithmic growth over a further 48 h
period. Forty-eight hours was chosen as an end-point for the
assay to allow the cells the potential to undergo at least three
doublings before assessing drug effects and to encompass
only the logarithmic phase of growth of the cells (doubling
times were between 13 and 15 h for all cell lines). Cisplatin
was dissolved in strile saline immediately prior to use. Novel
dicarboxylates were dissolved m ethanol and added to cell
Correspondence: R.M, Orr, Drug Development Section, The Insti-
tute of Cancer Research, Block E, 15 Cotswold Road, Belmont,
Sutton, Surrey SM2 5NG, UK.
Received 11 November 1993; and in revised form 9 March 1994.
( MacmiMn Prew Ltd., 1994 Dr. J. Cancer (1994), 70, 415-420416 R.M. ORR et al.
cultures to give a final concentration of 0.5% ethanol. This
concentration of ethanol did not inhibit cell growth over a
period of48 h. The IC50 values were defined as the concentra-
tion of compound required to reduce cell counts to 50% of
control after 48 h continuous exposure. Resistance factors of
less than 2-fold were within the acceptable experimental
errors in IC50 values in repeat experiments. Cell numbers
were assessed using a Coulter counter (model ZM). In cell
survival experiments, after 24 h exposure to either cisplatin
or JM221, cells at 2 x 0I mn-1 were centrifuged at 800g for
5 min, resuspended in fresh medium, serially diluted and
soft-agar colony assays carried out as recently described
(Nicolson et al., 1992). Plating eficiencies of control cultures
were 78% and 93% for L12IO/S and L1210/cis respec-
tively.
Platinuwn associted with whole cells, nuclei andDNA
Either cisplatin or JM221 was added to cells which were at a
cell density of 2 x I0 ml-'. After 24h, cells were centrifuged
at 800g for 5 mi, washed once with ice-cold phosphate-
buffered saline (PBS) and split into three aliquots for cellular,
nuclei and DNA extractions. For cellular platinum levels, cell
pellets were resuspended in water (2 x 107cellsml-'),
sonicated and platinum levels measured as previously de-
scribed (Nicolson et al., 1992). For nuclei preparations, the
washed cell pellets (approximately 5 x 107 cells) were resus-
pended in ice-cold PBS (106ml-') to give a single-cell suspen-
sion and Nonidet P40 added to a final concentration of
0.05% (w/v). Tubes were inverted several times and placed
on ice for 5 min. Intact nuclei were visualised by light micro-
scopy and counted. This technique resulted in efficient mem-
brane stripping with no loss of nuclei in these cell lines.
Following centrifugation at 800g for 5 min, nuclei were
resuspended in water (4 x 107ml-') and sonicated as for
cellular platinum. For DNA isolation, frozen cell pellets
(approximately 5 x 107 cells) were thawed into 2.5 ml of
lysing solution (0.4% SDS, 150 mM sodium chloride, 10 mM
EDTA, 1 mgml-' proteinase K, 10 mM Tris, pH 7.4) and
incubated at 65'C for 15 min and then at 37C overnight.
Lysates were extracted with an equal volume of phenol rea-
gent (Kirby, 1965) and, following centrifugation at 2,000g
for 20 min, the aqueous phase was removed, sodium acetate
added (0.3 M final concentration) and nucleic acids precipi-
tated by addition of 2.5 volumes of ethanol. After two
washes with 80% ethanoL the nucleic acids were pelleted by
centrifugation, dissolved in 4.5 ml of 10 mM Tris-0.1 mM
EDTA pH 7.7 and incubated with 25iLl of RNAse A (10 mg
ml-') at 37C for 30min. Solutions were re-extracted with
phenol reagent and DNA precipitated and collce as de-
scribed above. Dried DNA was digested in 250Id of 0.2%
nitric acid at 37C overnight. The platinum content of all
three preparations was measured by flameless atomic absorp-
tion spectroscopy using a Perkin Elmer 1IOOB/HGA 700
(detection limit 5 ngml-'). DNA content was assessed by the
measurement of 2'-deoxyribose units by the colorimetric
method of Burton (1956). Approximately 100 lg of DNA
was extracted per 107 cells. For direct comparison of results
between platinum associated with cell and nuclei sonicates
and extracted DNA, the results with the cell sonicates and
nuclei were normalised to their DNA rather than protein
content. A DNA fraction was prepared from both by a
modification of the method of Schmidt and Thannhauser
(1945). Briefly, 0.5ml of sonicate was added to 2.5ml of
ice-cold 0.2 M perchloric acid (PCA) and the precipitate col-
lected by centrifugation at 800 g for 10 min. The precipitate
was hydrolysed twice in 0.75ml of 1 M PCA at 70°C for
20 min followed by centrifugation. The two supernatants
were combined and the 2'-deoxyribose content measured as
referenced above. In the event that a small proportion of
RNA may have broken down during the procedure, alkaline-
hydrolysed RNA was added to the assay and found not to
interfere with the measurement of 2'-deoxyribose units. For
DNA platination experiments using L1210/S and L1210/cis
cells exposed to varying concentrations of cisplatin for 2 h,
expenments were initiated at a cell density of 4 x I0 ml-'
(I50ml per point) to obtain an optimal cell harvest for the
DNA extraction procedure. Comparisons between cellular,
nuclei or DNA-associated platinum were carried out using
Welch's alternative t-test, owing to the variances between
standard deviations and two-tailed P-values caculated.
Reuts
Growth-lay assays
IC50 values for all of the platinum(IV) dicarboxylates against
the L1210/S and platinum-reistant variants are shown in
Tabks I-III. Comparing JM222 with JM223 (Table I), in
which the amine ligand was isobutyl and the axial ligands
either acetato (JM222) or butyrato (JM223), potency in-
creased about 10-fold with extending the chain length of the
axial ligands. When the amine ligand was n-propyl and with
aryl substituents on the axial ligands (JM244), the IC50 value
was reduced almost 200-fold. The most active compound in
the alicyclic series of amne/amine dicarboxylates (axial
ligand = butyrato) was JM221 (R = cyclohexyl, Table H).
Table III shows the results obtained with cyclohexylamine/
ammines carrying various axial dicarboxylate ligands (ali-
phatic, branched-chain aliphatic and aromatic). As axial
straight-chain aliphatic substituents were extended in a step-
Table I Aliphatic amme/amine dcarboxylates
(CH3)2CHCH2NH2 loCI IC50 qw)
L1210/cis L1210/tetra L1210/carbo
Compound R L1210/S (10-fold) (34-fold) (14-fold)
JM222 CH3 5.5 5.9 (1.07) 4.5 (0.82) -
JM223 n-C3H, 0.4 0.4 (1.0) 0.29 (0.73) 0.28 (0.7)
JM244 Om 0.03 0.03 (1.0) 0.03 (1.0) 0.04 (1.3)
cH3(c2)9NH3 ' Pto-~
The results are the mean of two separate experiments (triplicate cultures per point in each
experiment). Figures in parentheses represent fold resistance. L1210/S, sensitive cell line; L1210/
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wise manner, so the potency of the compounds increased, e.g.
comparing JM216, JM231 and JM221 the butyrato axial
ligand (JM221) was the most effective. Branched-chain
aliphatics were less effective in producing growth delays com-
pared with their straght-chain counterparts. Overall, the
most active compounds in Table HI were those with aromatic
axial ligands (JM2644 and JM290). The IC_% values of
JM2644 and JM290 were similar to the IC5, value of JM244
(aromatic axial ligands, aliphatic amine ligand) in Table I.
All of the platinum(IV) amine/amine diarboxylates over-
came cisplatin, tetraplatin and carboplatin istance in these
L1210 lines, resistance factors being in the range of 0.4-2.
JM221 was selected for further comparative studies with
cisplatin as the most potent of the alicyclic compounds in
Table II.
Cell survival
Cell survival, as measured by colony-forming ability in soft
agar following a 2 h exposure to varying concentrations of
cisplatin, in the L1210/S and L1210/cis lines has been re-
ported elsewhere (Nicolson et al., 1992). In order to assess
the biochemical parameters associated with longer term
exposure to cisplatin or JM221 in the L1210/S and L1210/cis
lines, cell survival experiments were carried out following
24h exposure to either agent (Figure 1). The concentrations
of compounds that resulted in 25% clonogenic survival were
0.6 Mm cisplatin and 0.1 ps JM221 for L1210/S and 42pm
cisplatin and 0.15M JM221 for L1210/cis. The first three
drug treatments were seeted for further biochmical studies.
At these drug concentrations cells continued to cycle through
one doubling during the 24 h continuous exposure, and
viabilities, as ass by trypan blue dye exclusion, were
>90%. JM221 treatment of the L1210/cis line was omitted
owing to an apparent lack of cross-resistance in colony
assays.
Biochemistry
Following exposure of L1210/S and L1210/cis cells to vary-
ing concentratons of cisplatin (up to 100aum) for 2 h, the
L1210/cis line had approximately 50% less platinum associ-
ated with the DNA than the sensitive line at all drug concen-
trations (Figure 2). Viability studies (trypan blue dye
exclusion) showed both cell lines to be intact following 2 h
exposure to 100 LM cisplatin. At 10pm cisplatin for 2 h, cell
survival in clonogenic assays was 4% and 76% for L1210/S
and L1210/cis respectively. These studies were extended to
the measurement ofcellar, nuclei and DNA platinum bind-
ing in cells exposed to either cisplatin or JM221 for 24h at
concentrations which resulted in 25% survival. L1210/cis
cells exposed to a non-toxic concentration of cisplatin
(0.6 lsM) for 24 h were included for comparison with the
sensitive line. At equimolar concentrations of cisplatin
(0.6ElM) significantly less platinum was associated with the
cells and DNA of the L1210/cis line compared with L1210/S
(Table IV), whereas no statistical difference was shown with
nuclei and DNA bining although the means were lower.
However, at equitoxic concentrations of cisplatin (L1210/S,
0.61M; L1210/cis, 4.2 pM) considerably more cell-associated
Tab H Alicyclc ammine/amine dicarboxylates
H2CH2CH3
NH3\
RNH2/
\ C{ 2
W223IC.(w 'AAn2 %,2%3 IC-v (AM)
L1210/cis L1210/tetra L1210/carbo
C eound R L1210/S (10-fold) (34-fold) (14-fold)
JIM260 c-C4H7 0.18 0.22 (1.2) 0.20 (1.1) 0.26 (2.2)
JM229 c-C4H, 0.25 0.25 (1.0) 0.15 (0.6) 0.25 (1.0)
JM221 c-C*H, 0.06 0.11 (1.8) 0.06 (1.0) 0.12 (2.0)
JM271 c-C7HI3 0.12 0.15 (1.3) 0.11 (0.9) 0.26 (2.2)
The results are the mean of two separate pernts (tipicate cultures per point in each
experiment). Figures in parenthess represent fold resist e. L1210/S, sensitive cell line;
L1210/cis, cisplatin sistant; L1210/tetr tetraplatin resistant; L1210/carbo, carboplatin
resistant.
Tale m Cydohexylamine dicarboxylates
ICso (AM)
L1210/cis L1210/tetra L1210/carbo
Conm RI L1210/S (10-fold) (34-fold) (14-fold)
JM216 CH3 1.2 1.5 (1.3) 1.4 (1.2) 1.6 (1.3)
JM231 C2H5 0.31 0.35 (1.1) 0.18 (0.6) 0.39 (1.3)
JM221 n-C3H7 0.06 0.11 (1.8) 0.06 (1.0) 0.12 (2.0)
JM272 i-C3H7 0.14 0.1 (0.7) 0.07 (0.5) 0.21 (1.5)
JM262 t-C3H7 0.18 0.15 (0.8) 0.08 (0.4) 0.15 (0.8)
JM274 n-C4HI 0.05 0.08 (1.6) 0.05 (1.0) 0.08 (1.6)
JM273 t-C4H, 0.08 0.07 (0.9) 0.04 (0.5) 0.11 (1.4)
JM256 NHC2H5 1.27 1.38 (1.1) 0.79 (0.6) 1.58 (1.2)
JM321 NHC4H, 0.06 0.07 (1.2) 0.04 (0.7) 0.10 (1.7)
JM2644 Ph 0.03 0.03 (1.0) 0.03 (0.7) 0.03 (1.0)
JM290 Ph-NO2 0.04 0.05 (1.3) 0.04 (1.0) 0.05 (1.3)
lbe results are the mean of two separate experiments (triplicate culures per point in each
experiment). Fir i parentheses reptesent fold r t . L1210/S, sensitiv cell line; L1210/
cis, cisplatin istant; L1210/tetra, tetraplatin rnistat; L1210/carbo, carboplatin resistant.418 R.M. ORR et al.
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Fue 1 Cytotoxicity of cisplatin to L1210/S (@-@) or
L1210/cis (U-U) and JM221 to L1210/S (A-A) or L1210/cis
(O -0), in soft-agar colony assays following 24 h continuous
exposure. Each point represents the mean of four separate obser-
vations. Error bars representing ± s.d. are shown where they
exceed the size of the symbols.
50 100
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Figwe 2 Platinum binding to the DNA of L1210/S (- 0)
and L1210/cis (U-U) cells following 2h exposure to varying
concentrations of cisplatin. The results are the means of two
separate experiments. Error bars represent ± s.d.
Table IV Platinum associated with cells, nuclei and DNA of L1210 cells exposed to
equitoxic or equimolar concentrations of cisplatin (L1210/S L1210/cis) or equitoxic
concentrations of JM221 (L1210/S)
nmoles of Ptlg DNA
Treatment Cells Nuclei DNA
A. L12IO/S+O.6IM cisplatina 554 (±16.2) 110 (±19.1) 11.5 (±1.8)
B. L1210/S + 0.1ILM JM221' 2684 (_572) 154 (i39.5) 17.1 (+ 1.6)
C. L1210/cis + 0.6 M cisplatin 246 (±25.0) 75 (±25.5) 7.5 (± 1.2)
D. L1210/cis+ 4.2ipLm cisplatin' 2140 (±538) 272 (±71.1) 21.1 (±1.4)
a'The concentration of compound leading to 25% cell survival following 24 h
continuous exposure (see Figure 1). The results represent the mean (± s.d.) of three
separate experiments. Comparing A with B, cells P <0.05, nuclei P>0.05, DNA
P<0.05; A with C, cells P<0.001, nuclei P>0.05, DNA P>0.05; A with D, cells
P<0.05, nuclei P>0.05; DNA P<0.01; B with C, cells P<0.05, nuclei P>0.05,
DNA P<0.01; B with D, cells P>0.5, nuclei P>0.05, DNA P>0.05; C with D,
cells P <0.05, nuclei P <0.05, DNA P <0.01 using Welch's alternative t-test as
described in Materials and methods.
platinum (nearly 4-fold) and twice as much platinum was
associated with the nuclei and DNA of the L1210/cis line.
When the sensitive line was exposed to equitoxic concentra-
tions of either cisplatin or JM221, it was evident that nearly
five times more platinum was associated with whole cells
following JM221 exposure, even though the added drug con-
centration was 6-fold lower than cisplatin (Table IV).
Although more DNA platination (1.5-fold) was observed
after exposure to JM221 compared with cisplatin, there was
no significant difference between nuclear platinum concentra-
tions.
Discussio
Recently we showed that, although four series of novel
ammine/amine platinum(II) and platinum(lV) complexes,
broadly based on the structures of cisplatin, carboplatin,
tetraplatin and iproplatin, can overcome acquired resistance
to cisplatin in L1210 cells, the only class of compounds
which can overcome acquired resistance to tetraplatin is the
series of ammine/amine trans-dihydroxodichloroplatinum(IV)
complexes (Orr et al., 1993). Since this line is also sensitive to
the trans-dihydroxodichloroplatinum(IV) parent diammine, it
is apparent that the trans-dihydroxodichloro- ligand arrange-
ment alone confers sensitivity, whereas the nature of the
amine ligand determines potency. Now we are reporting a
novel class of ammine/amine platinum(IV) dicarboxylates
which can overcome acquired resistance to cisplatin, tetra-
platin and carboplatin in three variant L1210 lines. With
these dicarboxylates, it is apparent that the length and subs-
tituents of the axial ligands, as well as of the amine ligand,
strongly influence potency. For example, extending a
straight-chain aliphatic axial ligand from acetato to butyrato
increases the potency 14-fold when these compounds possess
a branched-chain amine ligand (comparing JM222 with
JM223) and 20-fold when these compounds have an alicycic
amine ligand (comparing JM216 with JM221). In addition,
the cyclohexylamine function confers greater potency on
these compounds (4- to 7-fold) than the corresponding
branched-chain aliphatic ligand (comparing JM216 with
JM222 and JM221 with JM223). This is in agreement with
the results of colleagues who have studied many of these
dicarboxylates, including JM216, JM222 and JM221, using a
panel of human ovarian cell lines with a broad spectrum of
sensitivity to cisplatin (Kelland et al., 1992). We also found
that the most active compounds against the L1210 lines were
those possessing aromatic axial ligands. These compounds
were approximately twice as potent as JM221, regardless of
whether the amine ligand was aliphatic (JM244) or alicycic
(JM2644). In cell survival experiments, following 24 h drug
exposure to L1210/S cells, JM221 was found to be 6-fold
more active than cisplatin, which prompted some preliminary
comparative assessments of cellular accumulation and DNA
binding.
Several studies have identified decreased intracellular
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platinum accumulation as one mechanism contributing to
acquired resistance to cisplatin in L1210 cells (Hromas et al.,
1987; Richon et al., 1987; Waud, 1987; Kraker & Moore,
1988). Recent characterisation of all of our resistant lines
demonstrated reduced platinum uptake following exposure to
cisplatin, tetraplatin or carboplatin, although this did not
correlate with the degree of resistance (Nicolson et al., 1992),
while glutathione levels remained unchanged. These studies
have been extended here to assess the degree of platinum
binding to DNA in L1210/cis cells compared with L1210/S
cells at equimolar and equitoxic concentrations of cisplatin.
As expected, the cellular platinum content was significantly
reduced in the L1210/cis line compared with the L1210/S line
at equimolar concentrations of cisplatin following 24 h
exposure, with lower amounts of platinum associated with
nuclei and DNA, although the difference was not statistically
significant. However, at equitoxic concentrations of cisplatin
more platinum was associated with cells, nuclei and the
extracted DNA from the resistant line than with the sensitive
line, indicating a greater overall tolerance to platinum in
L1210/cis cells. The L1210/cis cells had nearly four times
more cellular platinum, leading to twice the amount of
platinum bound to DNA, than the sensitive line at equitoxic
concentrations of cisplatin. Therefore, reduced platinum
uptake is only one feature of resistance in the L1210/cis line,
which is probably multifactorial. At the DNA level, an addi-
tional mechanism may be an enhanced capacity for DNA
repair, as others have documented using cisplatin-resistant
L1210 cell lines developed elsewhere (Sheibani et al., 1989).
At the cellular level, cell volume, protein content and
glutathione levels have not changed during the development
of acquired resistance to cisplatin (Nicolson et al., 1992; Orr
et al., 1993), and other workers have not found a role for
elevated metallothioneins in an L1210 line with acquired
resistance to cisplatin (Farnworth et al., 1990).
When L1210/S cells were exposed to equitoxic concentra-
tions of either cisplatin or JM221, nearly five times more
platinum was associated with the JM221-treated cells even
though the cells were exposed to a 6-fold lower concentration
of JM221 than of cisplatin. This is probably because of the
greater lipophilicity of JM221 (Giandomenico et al., 1991),
and this property may also contribute to the potency of some
of these dicarboxylates. However, from the experiments
reported here, we cannot determine whether the majority of
the platinum is intracellular or merely bound on/in the cell
membrane. Certainly, the amount of platinum bound to the
DNA of JM221-treated cells (1.5-fold greater than the
cisplatin-treated L1210/S cells) does not reflect the quantity
of platinum associated with whole cells. In vitro binding
studies of cisplatin or of JM221 at 10 lM to calf thymus
DNA over 24 h at 37°C showed that six times more cisplatin
was bound than JM221 (data not shown). Whether the
parent compound or an intracellular platinum(II) or (IV)
metabolite binds to the DNA in L1210 cells remains to be
determined. Certainly, the L1210/tetra line is cross-resistant
to the reduced platinum(II) metabolite JM118 [cis-ammine-
dichloro (cyclohexylamine)platinum(II)], whereas sensitivity
is retained with JM221. However, this cross-resistance may
be at the level of cellular uptake of compound.
In summary, platinum(IV) dicarboxylates represent
another class of platinum-containing agents which overcome
acquired resistance to cisplatin, tetraplatin and carboplatin in
L1210 cells. All of these lines exhibit reduced uptake of the
parent compound. However, studies with the L1210/cis line
here suggest that at least one other resistance mechanism
exists, possibly at the DNA level. Comparing cisplatin with
JM221 in the sensitive line at equitoxic concentrations, it is
apparent that the high levels of cellular platinum achieved
with JM221 contribute to the potency of this dicarboxy-
late.
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